Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Secondary nucleation and elongation occur at different sites on Alzheimer’s amyloid-β aggregates
Authors
Keywords
-
Journal
Science Advances
Volume 5, Issue 4, Pages eaau3112
Publisher
American Association for the Advancement of Science (AAAS)
Online
2019-04-18
DOI
10.1126/sciadv.aau3112
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Chemical Kinetics for Bridging Molecular Mechanisms and Macroscopic Measurements of Amyloid Fibril Formation
- (2018) Thomas C.T. Michaels et al. Annual Review of Physical Chemistry
- Secondary nucleation in amyloid formation
- (2018) Mattias Törnquist et al. CHEMICAL COMMUNICATIONS
- Loss of clusterin shifts amyloid deposition to the cerebrovasculature via disruption of perivascular drainage pathways
- (2017) Aleksandra M. Wojtas et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phage display and kinetic selection of antibodies that specifically inhibit amyloid self-replication
- (2017) Anna Munke et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibiting the Ca 2+ Influx Induced by Human CSF
- (2017) Anna Drews et al. Cell Reports
- Selective targeting of primary and secondary nucleation pathways in Aβ42 aggregation using a rational antibody scanning method
- (2017) Francesco A. Aprile et al. Science Advances
- Particle-Based Monte-Carlo Simulations of Steady-State Mass Transport at Intermediate Péclet Numbers
- (2016) Thomas Müller et al. INTERNATIONAL JOURNAL OF NONLINEAR SCIENCES AND NUMERICAL SIMULATION
- Clusterin Binds to Aβ1–42Oligomers with High Affinity and Interferes with Peptide Aggregation by Inhibiting Primary and Secondary Nucleation
- (2016) Marten Beeg et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Kinetic analysis reveals the diversity of microscopic mechanisms through which molecular chaperones suppress amyloid formation
- (2016) Paolo Arosio et al. Nature Communications
- Effect of CLU genetic variants on cerebrospinal fluid and neuroimaging markers in healthy, mild cognitive impairment and Alzheimer’s disease cohorts
- (2016) Lin Tan et al. Scientific Reports
- An anticancer drug suppresses the primary nucleation reaction that initiates the production of the toxic A 42 aggregates linked with Alzheimers disease
- (2016) J. Habchi et al. Science Advances
- Microfluidic Diffusion Analysis of the Sizes and Interactions of Proteins under Native Solution Conditions
- (2015) Paolo Arosio et al. ACS Nano
- Latent analysis of unmodified biomolecules and their complexes in solution with attomole detection sensitivity
- (2015) Emma V. Yates et al. Nature Chemistry
- A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers
- (2015) Samuel I A Cohen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- A molecular chaperone breaks the catalytic cycle that generates toxic Aβ oligomers
- (2015) Samuel I A Cohen et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Interaction of the Molecular Chaperone DNAJB6 with Growing Amyloid-beta 42 (Aβ42) Aggregates Leads to Sub-stoichiometric Inhibition of Amyloid Formation
- (2014) Cecilia Månsson et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The amyloid state and its association with protein misfolding diseases
- (2014) Tuomas P. J. Knowles et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Expression and Purification of Chaperone-Active Recombinant Clusterin
- (2014) Rebecca A. Dabbs et al. PLoS One
- Chemical kinetics for drug discovery to combat protein aggregation diseases
- (2014) Paolo Arosio et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Extracellular Chaperones and Proteostasis
- (2013) Amy R. Wyatt et al. Annual Review of Biochemistry
- Quantification of the Concentration of Aβ42 Propagons during the Lag Phase by an Amyloid Chain Reaction Assay
- (2013) Paolo Arosio et al. JOURNAL OF THE AMERICAN CHEMICAL SOCIETY
- Proliferation of amyloid- 42 aggregates occurs through a secondary nucleation mechanism
- (2013) S. I. A. Cohen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The Amyloid State of Proteins in Human Diseases
- (2012) David Eisenberg et al. CELL
- BRICHOS Domains Efficiently Delay Fibrillation of Amyloid β-Peptide
- (2012) Hanna Willander et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
- (2012) Iryna Benilova et al. NATURE NEUROSCIENCE
- Nucleated polymerization with secondary pathways. II. Determination of self-consistent solutions to growth processes described by non-linear master equations
- (2011) Samuel I. A. Cohen et al. JOURNAL OF CHEMICAL PHYSICS
- Nucleated polymerization with secondary pathways. I. Time evolution of the principal moments
- (2011) Samuel I. A. Cohen et al. JOURNAL OF CHEMICAL PHYSICS
- Molecular chaperones in protein folding and proteostasis
- (2011) F. Ulrich Hartl et al. NATURE
- The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics
- (2011) Eric Karran et al. NATURE REVIEWS DRUG DISCOVERY
- The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-β1−40 peptide
- (2011) Priyanka Narayan et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Extracellular chaperones modulate the effects of Alzheimer’s patient cerebrospinal fluid on Aβ1-42 toxicity and uptake
- (2009) Justin J. Yerbury et al. CELL STRESS & CHAPERONES
- An Analytical Solution to the Kinetics of Breakable Filament Assembly
- (2009) T. P. J. Knowles et al. SCIENCE
- α2-Macroglobulin and Haptoglobin Suppress Amyloid Formation by Interacting with Prefibrillar Protein Species
- (2008) Justin J. Yerbury et al. JOURNAL OF BIOLOGICAL CHEMISTRY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started